Skip to main content
Clinical Trials/NCT02594605
NCT02594605
Completed
Phase 2

Investigation of the Contributions of Platelet Rich Fibrin Combined With Conventional Periodontal Flap on Periodontal Healing

Ataturk University1 site in 1 country16 target enrollmentDecember 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Chronic Periodontitis
Sponsor
Ataturk University
Enrollment
16
Locations
1
Primary Endpoint
Levels of IGF-1, VEGF, BMP-2, FGF-2 on Weekly
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Platelet rich fibrin is a second generation platelet concentration which contains various growth factors. The aim of this study is to evaluate the clinical and biochemical efficacy of PRF in subjects of chronic periodontitis in the operation of conventional periodontal flap.

Detailed Description

PRF was developed in 2001 by Choukroun in France, it was the second generation fibrin adhesive, and was used to accelerate the soft and hard tissue healing. Many studies have shown beneficial effects of PRF on osteoconductive filler material in sinus lift operations, treatment of periodontal sulcus defect and treatment of furcation defects. Also PRF contains many growth factors. PRF accelerates periodontal regeneration through the gradually excreted growth factors and contributes to the bone regeneration. In this study, the investigators evaluated the effect of PRF on growth factors and its contribution to periodontal regeneration in subjects with chronic periodontitis.

Registry
clinicaltrials.gov
Start Date
December 2012
End Date
December 2013
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Alper KIZILDAĞ

Health Sciences Institute

Ataturk University

Eligibility Criteria

Inclusion Criteria

  • Patients with CP who had pocket depth ≤ 5 mm and at least two area (grouped as Control and PRF) with horizontal bone loss after Phase I therapy

Exclusion Criteria

  • The subjects excluded in the study had history of systemic disease, were smokers, had allergy to any drug, had need for prophylaxis of antibiotic and had taken antibiotics at least 6 months

Outcomes

Primary Outcomes

Levels of IGF-1, VEGF, BMP-2, FGF-2 on Weekly

Time Frame: 4 weeks

Change from baseline IGF-1, VEGF, BMP-2, FGF-2 levels of GCF at 1 month were measured by periopaper.

Secondary Outcomes

  • Alteration of Clinical Attachment Level(6 month)
  • Alteration of Periodontal Pocket Depth(6 month)

Study Sites (1)

Loading locations...

Similar Trials